Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IPCALAB | NSE
7.90
0.54%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
21/04/2026
1,476.50
1,469.90
1,491.00
1,462.10
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive anti-malarial diuretic DMARD and anthelmintic. The company provides generic and branded formulations in the therapeutic segments including allergy anti-neoplastic/cancer drugs anti-arthritic anti-epileptic anti-hypertensive cardiology dermatology diabetology gastroenterology haematology neurology ophthalmology rheumatology and urology as well as respiratory psychiatry probiotics orthopedics oral anti diabetes drug nutraceuticals NSAIDs neuropathic pain malaria infectious diseases immunosuppressant hepatoprotectives helminthics fever and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai India.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Midcap (2B - 10B USD)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
10.6%1 month
28.0%3 months
24.4%6 months
32.1%72.46
-
6.60
0.23
0.13
30.35
5.22
-
13.42B
374.59B
4.01B
0.12
14.04
18.10
31.80
7.67
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
77.00
Range1M
206.00
Range3M
232.20
Rel. volume
0.84
Price X volume
294.16M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Ajanta Pharma Limited | AJANTPHARM | Drug Manufacturers-Specialty & Generic | 2791.2 | 353.54B | 0.36% | 47.17 | 0.99% |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | Drug Manufacturers-Specialty & Generic | 1992.9 | 309.53B | 0.09% | 51.20 | 12.92% |
| Wockhardt Limited | WOCKPHARMA | Drug Manufacturers-Specialty & Generic | 1407.7 | 215.97B | 0.30% | n/a | 70.14% |
| AstraZeneca Pharma India Limited | ASTRAZEN | Drug Manufacturers-Specialty & Generic | 8452 | 211.30B | -0.93% | 197.18 | 0.65% |
| Neuland Laboratories Limited | NEULANDLAB | Drug Manufacturers-Specialty & Generic | 14920 | 209.50B | -1.86% | 53.76 | 7.44% |
| Dr. Reddy's Laboratories Limited | DRREDDY | Drug Manufacturers-Specialty & Generic | 1220.6 | 203.34B | -0.97% | 20.23 | 10.41% |
| Piramal Pharma Limited | PPLPHARMA | Biotechnology | 150.81 | 199.37B | 1.36% | 805.68 | 59.54% |
| NATCO Pharma Limited | NATCOPHARM | Drug Manufacturers-Specialty & Generic | 1055.65 | 189.08B | -4.04% | 15.31 | 6.34% |
| Eris Lifesciences Limited | ERIS | Drug Manufacturers-Specialty & Generic | 1376 | 187.55B | -3.94% | 48.08 | 107.55% |
| Syngene International Limited | SYNGENE | Biotechnology | 444.65 | 178.39B | 1.88% | 71.45 | 13.66% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| AFFLE | AFFLE | Advertising Agencies | 1462.9 | 204.59B | 1.25% | 67.64 | 7.31% |
| Vedant Fashions Limited | MANYAVAR | Apparel Retail | 450.85 | 110.28B | 0.48% | 84.26 | 27.74% |
| Vertoz Advertising Limited | VERTOZ | Advertising Agencies | 50.53 | 44.32B | -5.04% | 48.67 | 10.74% |
| Signpost India Limited | SIGNPOST | Advertising Agencies | 271.87 | 15.94B | 0.54% | 30.54 | 80.30% |
| "SAI SILKS (KALAMANDIR) LIMITED " | KALAMANDIR | Apparel Retail | 100.64 | 14.83B | -0.92% | 28.83 | 43.67% |
| V2 Retail Limited | V2RETAIL | Apparel Retail | 197.59 | 7.05B | 3.12% | 120.49 | 191.28% |
| Bhagyanagar India Ltd | BHAGYANGR | Copper | 214.72 | 6.94B | -0.03% | 36.36 | 52.08% |
| Madhav Copper Limited | MCL | Copper | 61 | 1.68B | -1.98% | 82.22 | 32.14% |
| Cubex Tubings Limited | CUBEXTUB | Copper | 93.13 | 1.35B | 1.38% | 35.85 | 21.78% |
| Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 74.4 | 829.47M | -0.24% | 50.06 | 4.88% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 30.35 | 24.85 | Expensive |
| Ent. to Revenue | 5.22 | 11.40 | Cheaper |
| PE Ratio | 72.46 | 51.36 | Expensive |
| Price to Book | 6.60 | 6.83 | Par |
| Dividend Yield | 0.12 | 0.52 | Poor |
| Std. Deviation (3M) | 24.42 | 42.17 | Lower Risk |
| Debt to Equity | 0.23 | 0.35 | Cheaper |
| Debt to Assets | 0.13 | 0.17 | Cheaper |
| Market Cap | 374.59B | 290.82B | Market Leader |